Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

XTLB Relative to the S&P 500

XTLB Relative to the Sector

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the XTL Biopharmaceuticals Ltd. (NASD:XTLB) seasonal charts above shows that a Buy Date of December 27 and a Sell Date of March 31 has resulted in a geometric average return of 13.06% above the benchmark rate of the S&P 500 Total Return Index over the past 19 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 19 years by an average of 44.35% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren’s syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

To download XTLB seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: XTLB